Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Plummer

Showing results (91-100 of 161) with videos related to

Pageof 17
Sort By:
Cancer Immunology, Immunotherapy : CII|August 12, 2011
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacyRiccardo Danielli, Ruggero Ridolfi, Vanna Chiarion-Sileni, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
British Journal of Cancer|August 2, 2018
Detection of circulating tumour cell clusters in human glioblastomaIlona Krol, Francesc Castro-Giner, Martina Maurer, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2023
Programmed cell death-1 receptor-mediated regulation of Tbet<sup>+</sup>NK1.1<sup>-</sup> innate lymphoid cells within the tumor microenvironmentJing Xuan Lim, Chester Y Lai, Grace E Mallett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumorsBalaji Venugopal, Richard Baird, Rebecca S Kristeleit, et al.
JAMA Dermatology|June 30, 2018
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical TrialMarina Danilenko, Elaine Stamp, Deborah D Stocken, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Clinical Pharmacokinetics|March 17, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentChristian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, et al.
BMC Cancer|June 14, 2024
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort studyAbigail Gault, Linda Hogarth, Kristian C Williams, et al.
Pageof 17

Showing results (91-100 of 161) with videos related to

Sort By:
Pageof 17
Cancer Immunology, Immunotherapy : CII|August 12, 2011
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacyRiccardo Danielli, Ruggero Ridolfi, Vanna Chiarion-Sileni, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
British Journal of Cancer|August 2, 2018
Detection of circulating tumour cell clusters in human glioblastomaIlona Krol, Francesc Castro-Giner, Martina Maurer, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2023
Programmed cell death-1 receptor-mediated regulation of Tbet<sup>+</sup>NK1.1<sup>-</sup> innate lymphoid cells within the tumor microenvironmentJing Xuan Lim, Chester Y Lai, Grace E Mallett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumorsBalaji Venugopal, Richard Baird, Rebecca S Kristeleit, et al.
JAMA Dermatology|June 30, 2018
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical TrialMarina Danilenko, Elaine Stamp, Deborah D Stocken, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Clinical Pharmacokinetics|March 17, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentChristian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, et al.
BMC Cancer|June 14, 2024
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort studyAbigail Gault, Linda Hogarth, Kristian C Williams, et al.
Pageof 17